We are proud to announce initiation of a Phase 1/1b clinical trial of our antibody candidate SRF617, one of the few clinical-stage candidates targeting the immunosuppressive protein CD39. Read more here: https://t.co/m9YeipKVam
#biotech https://t.co/IhJf309aSd